作者
Yoshihiro Harano,Masanori Yamamoto,Tetsuro Shimura,Munenori Okubo,Yutaka Koyama,Ryo Yamaguchi,Ai Kagase,Takahiro Tokuda,Fumiaki Yashima,Shinichi Shirai,Norio Tada,Toru Naganuma,Masahiro Yamawaki,Futoshi Yamanaka,Kazuki Mizutani,Masahiko Noguchi,Hiroshi Ueno,Kensuke Takagi,Yohei Ohno,Masaki Izumo,Hidetaka Nishina,Masahiko Asami,Toshiaki Otsuka,Yusuke Watanabe,Kentaro Hayashida,Kentaro Hayashida,Makoto Tanaka,Hikaru Tsuruta,Tetsuya Saito,Yusuke Kobari,Toshinobu Ryuzaki,Tatsuo Takahashi,Shinichi Goto,Shohei Imaeda,Shingo Sakata,Yoshinori Katsumata,Kohsuke Shirakawa,Juri Iwata,Keitaro Shinada,Akiyoshi Kajino,Jungo Kato,Ryo Arita,T. Moriizumi,Masanori Yamamoto,Mitsuru Sago,Tatsuya Tsunaki,Ryo Yamaguchi,Junji Yanagisawa,Yuki Okubo,Ai Kagase,Takahiro Tokuda,Yuki Nakashima,Toshihiro Kobayashi,Kenichi Shibata,Ryoutaku Kawahata,Hiroto Nishio,Yuki Kondo,Tomofumi Nakamura,Hiroshi Tsunamoto,Tetsuro Shimura,Yutaka Koyama,Munenori Okubo,Shunsuke Imai,Tokuya Sakakura,Yoshihiro Harano,M. Inagaki,Hirooki Higami,Yoji Kuze,Takashi Nagai,Azusa Kurita,Shinichi Shirai,Akihiro Isotani,Kenichi Ishizu,Masato Fukunaga,Hiroyuki Tabata,Toru Morofuji,Hiroyuki Kono,Maiko Kuroda,Euihong Ko,Norihisa Miyawaki,Kenji Nakano,K. Miyahara,Ko Yamamoto,Koumei Onuki,Yasuo Tsuru,Tomohiro Suenaga,Akira Otani,Yusuke Watanabe,Taiga Katayama,Hirofumi Hioki,Jun‐ichi Nishikawa,Yosei Iseki,Yasuyuki Tsuchida,Kento Kito,Jo Omiya,Masataka Arakawa,Maki Okamoto,Masafumi Saito,Mizuki Miura,Toru Naganuma
摘要
Background The Direct Oral Anticoagulant (DOAC) Score can predict bleeding risk in patients with atrial fibrillation taking DOACs; however, it lacks external validation. Therefore, this study aimed to assess the association between the DOAC Score and bleeding events in patients with atrial fibrillation who underwent transcatheter aortic valve replacement. Methods and Results This retrospective multicenter cohort study included patients with atrial fibrillation who underwent transcatheter aortic valve replacement, as registered in a Japanese multicenter registry. The primary end point was the incidence of bleeding. Patients were categorized based on their DOAC Score: low and moderate‐ (≤7 points), high‐ (8–9 points), and very high‐risk (≥10 points) groups. Among 1230 patients (mean age 84.6±5.1 years; 457 men), 465 (37.8%) received a vitamin K antagonist, and the remaining patients received DOACs. The low and moderate‐, high‐, and very high‐risk groups included 380 (30.1%), 497 (40.4%), and 353 patients (28.7%), respectively. The 3‐year cumulative incidence of all bleeding events was significantly different among the 3 groups (low and moderate risk: 6.6%, high risk: 6.9%, and very high risk: 14.0%; P <0.01). Multivariable Cox regression analysis revealed that significant increments in the DOAC Score were associated with a risk of all bleeding events at 3 years in the overall cohort (hazard ratio [HR], 1.22 [95% CI, 1.08–1.38]; P <0.01), in the DOAC cohort (HR, 1.20 [95% CI, 1.01–1.42]; P =0.04), and in the vitamin K antagonist cohort (HR, 1.25 [95% CI, 1.04–1.50]; P =0.02). Conclusions The DOAC Score was significantly associated with bleeding events in patients with atrial fibrillation after transcatheter aortic valve replacement, aiding in clinical decision‐making for anticoagulant management. Registration URL: https://center6.umin.ac.jp/cgi‐open‐bin/ctr_e/ctr_view.cgi?recptno=R000023585 ; Unique identifier: UMIN000020423.